Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | 12-2024 | 06-2024 | 12-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,245 | 3,638 | 4,775 | 6,818 | 7,719 |
| Receivables | 966 | 754 | 912 | 835 | 762 |
| TOTAL | $3,210 | $4,392 | $5,687 | $7,653 | $8,481 |
| Non-Current Assets | |||||
| PPE Net | 2,730 | 3,674 | N/A | 2,599 | N/A |
| Investments And Advances | 180 | 162 | 156 | 148 | 162 |
| Intangibles | 57 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 393 | 434 | 377 | 9 | 10 |
| TOTAL | $3,360 | $4,270 | $533 | $2,756 | $173 |
| Total Assets | $6,571 | $7,369 | $8,050 | $9,375 | $10,290 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 30 | 28 | 28 | 26 | 30 |
| Accounts payable and accrued liabilities | 376 | 323 | 233 | 398 | 197 |
| Other current liabilities | 132 | 88 | 3 | 115 | 4 |
| TOTAL | $553 | $444 | $264 | $543 | $233 |
| Non-Current Liabilities | |||||
| Long Term Debt | 293 | 289 | 288 | 309 | 319 |
| TOTAL | $340 | $306 | $288 | $309 | $319 |
| Total Liabilities | $892 | $749 | $553 | $853 | $552 |
| Shareholders' Equity | |||||
| Common Shares | 18,707 | 17,416 | 17,558 | 17,979 | 17,541 |
| Retained earnings | -13,438 | -10,868 | -9,903 | -9,347 | -7,659 |
| Other shareholders' equity | 351 | 18 | -158 | -109 | -144 |
| TOTAL | $5,678 | $6,620 | $7,498 | $8,523 | $9,738 |
| Total Liabilities And Equity | $6,571 | $7,369 | $8,050 | $9,376 | $10,290 |